Vertex Pharmaceuticals Announces Results From Phase 2b AMPLIFIED Study Of Inaxaplin In People With Kidney Disease And Type-2 Diabetes; Treatment With Inaxaplin Led To Reduction In Urine Albumin To Creatinine Ratio Of -42.7% At Week 13 Compared To Baseline; Inaxaplin Was Generally Safe And Well Tolerated In Both Cohorts

뉴스 본문을 불러오고 있어요.

Vertex Pharmaceuticals Announces Results From Phase 2b AMPLIFIED Study Of Inaxaplin In People With Kidney Disease And Type-2 Diabetes; Treatment With Inaxaplin Led To Reduction In Urine Albumin To Creatinine Ratio Of -42.7% At Week 13 Compared To Baseline; Inaxaplin Was Generally Safe And Well Tolerated In Both Cohorts | 웨이프 WAPE

기사 요약

관련 종목

댓글 —